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Abstract: 21 
Background: The annual Hajj and Umrah are one of the largest recurring religious mass 22 
gatherings across the globe drawing pilgrims from more than 185 countries.  The living 23 
circumstances and activities of the pilgrims may create an environment for the occurrence and 24 
spread of communicable diseases.  Each year, the Health authority of the Kingdom of Saudi 25 
Arabia, in coordination with international health authorities, updates health requirements for 26 
pilgrims.   The Hajj for 2017 took place from August 24 to September 5, 2017.  Here, we review 27 
the expected obligations for immunizations for the 2018 Hajj and Umrah. 28 
Results: 29 
The  Hajj and Umrah vaccine requirements include mandatory vaccinations against yellow fever, 30 
quadrivalent meningococcal polysaccharide (every 3 years) or conjugated (every 5 years) 31 
vaccines and poliomyelitis vaccine.  Influenza vaccine utilizing the 2016 (Southern Hemisphere 32 
vaccine to all pilgrims) was recommended but was not obligatory for pilgrims.   Ciprofloxacin is 33 
required for individuals > 12 years excluding pregnant women as chemoprophylaxis to be given 34 
at the port of entry for Pilgrims coming from the meningitis belt. With the ongoing outbreaks of 35 
measles in Europe, it is recommended that all pilgrims have an updated immunization against 36 
vaccine-preventable diseases (diphtheria, tetanus, pertussis, polio, measles and mumps).  37 
Conclusion:  The mandatory vaccines remain the same with continued vigilance for the 38 
development of any new or emerging infectious diseases. Continuing surveillance for Zika virus, 39 
cholera and MERS-CoV are ongoing.  40 
41 
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Introduction: 42 
The annual Hajj and Umrah are one of the largest recurring religious mass gatherings across 43 
the globe drawing pilgrims from more than 185 countries.  The number of pilgrims from each 44 
country is determined based on the number of Muslims in each country and is based on a ratio 45 
of one pilgrim per one thousand Muslims in that country [1].  The Hajj season occurs at a 46 
fixed time each year from the 8th to the 13th day of the 12th month (Dhu al-Hijjah) in the 47 
Islamic calendar which is 11 days shorter than the Gregorian calendar.  Thus, the Hajj season 48 
occurs in different time of the Gregorgian calendar.  On the other hand, the Umrah season is 49 
year round and is more intense during the month of Ramadhan (the month of fasting).  The 50 
month of Ramadhan occurred May 27 to June 24, 2017 and will take place May 15 to June 51 
14, 2018.   Hajj is compulsory for all Muslims who have the resources once in a life time and 52 
the Umrah is not compulsory.  The number of the annual Hajj pilgrims is about three million 53 
with two million non-Saudis pilgrims arriving from overseas countries and mainly arriving by 54 
air and others from neighboring countries may travel via land [2–4].  In 2016, the majority 55 
(94%) of pilgrims arrived by air, 5% arrived by land and only 1% arrived through the sea. 56 
The number of pilgrims per year is shown in figure 1.  The Kingdom of Saudi Arabia (KSA) 57 
provides healthcare free of charge to all pilgrims during the Hajj as done previously through 58 
25 hospitals which have 5000 beds including 500 critical care beds and 550 emergency care 59 
beds and 155 healthcare centers staffed with 30,000 Ministry of Health staff [2–4].  In this 60 
year's Hajj more than 540,000 pilgrims were serviced in these healthcare facilities with 61 
emergency departments serving 23,000 pilgrims. The annual required vaccinations for the 62 
Hajj and Umrah seasons are issued by the Saudi Ministry of Health including the 2017 63 
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recommendations [5].  In this article we summarize the recommended vaccinations for the 64 
2017 Hajj and Umrah season. 65 
Medical Advice for Hajj and Umrah travelers: 66 
Each year the Saudi Ministry of Health publishes Hajj and Umrah requirements with emphasis 67 
on the required vaccinations.  These guidelines are updated annually to reflect the changes in the 68 
epidemiology of important infectious diseases [1,2,6,7].  The mandatory and recommended 69 
vaccines for the 2017 season are discussed further.  70 
Vaccination during the 2017 Hajj and Umrah Season: 71 
The vaccination requirements during the Hajj and Umrah are divided into: mandatory 72 
vaccinations (Meningococcal vaccination, Poliomyelitis vaccine, and Yellow Fever vaccine); 73 
recommended vaccination (Influenza), and other immunization against vaccine-preventable 74 
diseases (diphtheria, tetanus, pertussis, polio, measles and mumps). 75 
Meningococcal vaccination: 76 
Niesseria meningitides is associated with a high rate of carriage of 80% [8].   In a recent study, 77 
3.4% of 1055 arriving pilgrims were classified as nasopharyngeal carriage of N. meningitides 78 
and of them 66.7% had serogroup B [9].  The requirement of the meningococcal vaccination for 79 
pilgrims came in effect in 1987 after the occurrence of meningococcal outbreaks. [2]The vaccine 80 
initially was a bivalent A and C meningococcal vaccine and then was expanded to be a 81 
quadrivalent vaccine quadrivalent (A,C,Y, W135) in May 2001 [10,11].   This expansion of the 82 
vaccine resulted from the occurrence of two meningococcal outbreaks with serogroup W135 in 83 
2000 and 2001 [12–14].  The mean numbers of Hajj-related invasive meningococcal disease 84 
cases decreased from 13 to 2 cases per year in 1995 compared to 2011 [11].  The requirement of 85 
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the quadrivalent meningococcal vaccine includes all pilgrims from any country.  Either 86 
polysaccharide or conjugated vaccine could be used with differing need for re-dosing according 87 
to ministry of health guidance (every 3 yrs for the polysaccharide vaccine while for the 88 
conjugated vaccine every 5 yrs). The advantages of the conjugated vaccine include the ability to 89 
eradicate carriage and prevent outbreaks among returning colonized pilgrims. Moreover, 90 
ciprofloxacin (500 mg tablets) is administered as an oral chemoprophylaxis to pilgrims arriving 91 
from the African meningitis belt [2,6,8,15,16].  In one study, the carriage rate of N. meningitides 92 
was 3.6% and 1.4% in a paired cohort of pilgrims from high endemic countries at arrival and 93 
departure, respectively [9].   In an earlier study, the carriage rate of N. meningitidis after a single 94 
dose of ciprofloxacin was 5.2% before and 4.6% after the Hajj (P = 0.65) [17].  The carriage rate 95 
of N. meningitides among returning pilgrims varies from 0% to 0.6% [17–20]  and thus 96 
ciprofloxacin was not adopted as a strategy post-Hajj.  The compliance rate with the 97 
recommended meningococcal vaccination among arriving international pilgrims is 97-100% [9]. 98 
In one study 1055 arriving pilgrims at King Abdul Aziz International Airport, 98% of the 99 
pilgrims had the quadrivalent polysaccharide vaccine and 2% had the quadrivalent 100 
meningococcal conjugate vaccine (MCV4) [9].  Recently, N. meningitidis serogroup B is 101 
becoming an important cause of meningococcal meningitis in  Europe, Australia, and north 102 
America and may cause outbreaks [21–24].  Currently, a vaccine is available against N. 103 
meningitidis serogroup B [25] and there is no sufficient data to recommend the addition of this 104 
vaccine to the required Hajj vaccines [9]. An ideal meningococcal vaccine would contain the 4 105 
currently available serogroups in addition to serogroup B.  106 
Poliomyelitis: 107 
Poliomyelitis is a vaccine preventable disease; however, poliomyelitis eradication is hindered by 108 
the potential spread by international travelers [26].  There are reports of Hajj associated 109 
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poliomyelitis cases. In a mathematical model, it was estimated that there is a potential of 21 110 
importations of poliovirus into Saudi Arabia via Hajj pilgrims [27].  There are many countries 111 
which harbor patients infected with the Wild Polio Virus 1 or having a Vaccine Derived Polio 112 
Virus such as: Afghanistan, Nigeria and Pakistan.  There are also countries which are prone to 113 
have re-infection of patients such as: Cameroon, Central African Republic, Chad, Guinea, Laos 114 
People’s Democratic Republic, Madagascar, Myanmar, Niger, and Ukraine.  And there are 115 
countries which are open to have Poliomyelitis: Democratic Republic of the Congo, Equatorial 116 
Guinea, Ethiopia, Iraq, Kenya, Liberia, Sierra Leone, Somalia, South Sudan, Syrian Arab 117 
Republic and Yemen.  The Hajj requirement for those people coming from these three areas is 118 
summarized in table 1. In a recent study of vaccination compliance among pilgrims showed that 119 
99.5% of pilgrims coming from at-risk countries: Pakistan, India, Nigeria, or Afghanistan had 120 
poliomyelitis vaccination [28].  121 
Yellow Fever Vaccinations: 122 
The International Health Regulations (IHR) requires documentation of yellow fever vaccines 123 
for travelers from areas at risk of yellow fever transmission [29].  Although, yellow fever 124 
vaccination was considered valid for 10 years, the WHO World Health Assembly adopted an 125 
amended resolution that the yellow fever vaccination will be sufficient for the duration of the 126 
life of the vaccinated person starting July 11, 2017.  This new guidelines apply to existing and 127 
new certificates and the validity begins 10 days after the date of vaccination [30].   The 2016 128 
updated International travel and health lists the following countries as at risk of yellow fever 129 
[31]: Africa (Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, 130 
Chad, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, 131 
Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Mali, Mauritania, Niger, 132 
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Nigeria, Senegal, Sierra Leone, South Soudan, Sudan, Togo and Uganda), and Americas 133 
(Argentina, the Bolivarian Republic of Venezuela, Brazil, Colombia, Ecuador, French 134 
Guyana, Guyana, Panama, Paraguay, Peru, Plurinational State of Bolivia, Suriname and 135 
Trinidad and Tobago). 136 
Influenza vaccinations: 137 
The prevalence of the occurrence of influenza virus among pilgrims varies depending on the 138 
study and ranges from 0-5% to 28.6% (average of 9.2%) in various studies [20,32–48] (figure 2). 139 
The impact of the pandemic H1N1 influenza was evaluated in five studies [36,41–43,45]. The 140 
largest study included 2699 departing pilgrims and 0.1% were positive for H1N1 virus [43] and 141 
other studies showed a prevalence of less than 2% [36,42].   Influenza vaccine decreases 142 
development of influenza like-illness among pilgrims [49].   The compliance with influenza 143 
vaccination varies from 7.1% to 100% with an overall compliance of 96.3% [49–51].  The 144 
occurrence of the mismatch between vaccine and circulating influenza strains occur frequently 145 
and affect the Hajj pilgrims [52].  Currently, it is recommended that all pilgrims and Umrah 146 
visitors receive seasonal influenza vaccination [5].  However, influenza vaccine is currently not 147 
obligatory for pilgrims.  The issue of influenza vaccine availability to match Southern and 148 
Northern hemispheres was discussed by the Saudi Ministry of Health in consultation with the 149 
World Health Organization and it was recommended to use the available hemisphere strain as 150 
long as there is a match in circulating strains.Middle East Respiratory Syndrome Coronavirus 151 
(MERS-CoV): 152 
The initial description of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was 153 
few weeks before the 2012 Hajj season  [34,41,53].  Subsequently, the following Hajj and 154 
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Umrah seasons witnessed no transmission of MERS-CoV among pilgrims.  Methodical 155 
screening of departing pilgrims was evaluated among a large number of visitors with no evidence 156 
of MERS transmission [20,28,38,40,44,46,47,53–58].  It is advisable that pilgrims adhere to 157 
hand hygiene and follow the cough etiquette and avoid contacts with camels [2]. 158 
Pneumococcal Disease: 159 
The available literature shows that 7-37% of pilgrims are older adults (> 65 years of age), and 160 
that the compliance with age specific pneumococcal vaccine among pilgrims is 5% [59].  In a 161 
recent review, the carriage of pneumococcal vaccine serotype was higher in the post-Hajj perioid 162 
compared to the pre-Hajj period [60].  However, the available data do not support a firm 163 
recommendation for the S. pneumoniae vaccination of all pilgrims. 164 
Cholera and Diarrheal Diseases: 165 
Only few reports describe the specific incidence and etiology of diarrhea among pilgrims [61]. 166 
Cholera caused multiple outbreaks during the Hajj and the last ones were after the Hajj in 1984-167 
86 and 1989 [62,63].  Multiple factors contribute to diarrheal illness during the Hajj including 168 
inadequate food hygiene, presence asymptomatic carriers of bacteria, and mass food preparation. 169 
Cholera continues to cause outbreaks around the globe.   World health Organization (WHO) 170 
reported an outbreak of cholera in Kenya and in Yemen, where the cases in the latter reached 171 
500,000 [64,65].   There are no recent cholera outbreaks among pilgrims.  The Ministry of 172 
Health of Saudi Arabia takes active role in observing arriving pilgrims from areas with active 173 
cholera outbreaks and initiate quarantine and contact tracing once a case is suspected [2].  In 174 
addition, early detection of cases and timely treatment once the pilgrims are diagnosed.  There 175 
had been extensive improvement and availability of water sources and good sewage systems. 176 
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Currently, there is no mandatory cholera vaccine for pilgrims arriving from countries with 177 
cholera outbreaks.   178 
Measles and Rubella: 179 
There are multiple recent outbreaks of measles around the globe.  However, to date no reported 180 
outbreaks of measles during the Hajj.  Few studies confirmed the occurrence of measles in 181 
relation to other mass gatherings and had been reported and had been recently reviewed [66]. 182 
One measles outbreak took place in Pennsylvania, USA in an international youth sporting event 183 
[67].   The index case was a twelve year-old child, and seven (0.32%) of 1250 contacts in 8 states 184 
were diagnosed with measles [67].  Two other measles outbreaks occurred among attendees of a 185 
church gathering and in the 2010 Taizé festival in France [68,69]. 186 
Most patients were young adults and were unvaccinated. Currently, the Saudi ministry of health 187 
as always makes a strong recommendation that all pilgrims are to update their immunization 188 
against vaccine-preventable diseases (diphtheria, tetanus, pertussis, polio, measles and mumps) 189 
before coming to Umrah or Hajj.  Due to the occurrence of outbreaks of measles, there is a 190 
potential spread among susceptible populations. The European CDC strongly recommends 191 
measles immunization for non-immune pilgrims attending the Hajj [70].  192 
193 
Vector Borne Viruses (Zika and Dengue): 194 
The concern of Zika, Dengue virus and other flaviviruses remain a valid point in the case of mass 195 
gatherings such as the Hajj and Umrah.  Zika may produce asymptomatic infection in up to 80% 196 
of infected population [71].  The situation might be complicated by the presence of Aedes 197 
aegyptii in the surrounding cities of the Hajj and Umrah areas.  The mosquito transmitting zika 198 
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virus is the vector of the Yellow fever virus, Dengue Virus and chikungunya virus [72].  In a 199 
study of 159 cases of Dengue fever, only two patients were pilgrims [73]. Thus, despite the lack 200 
of large studies, it is thought that Dengue virus infection remains limited during the Hajj and 201 
Umrah.  Thus, pilgrimages during the Hajj and Umrah are advised to take measures to avoid 202 
insect bite to reduce the risk of infection with Dengue and other mosquito borne diseases.  203 
Antimicrobial Resistance: 204 
A recent systematic review showed a high prevalence and/or a high risk of acquisition of MDR-205 
bacteria in pilgrims during the Hajj [74].  Diarrhea and the use of antibiotics for upper 206 
respiratory tract infection were the strongest determinants of extended spectrum betalactamase 207 
producing Enterobacteriace acquisition in one study [75]. Overuse of antibiotics by Hajj pilgrims 208 
should be discouraged. 209 
Conclusion and comments: 210 
Each year, the planning for the following Hajj and Umrah season take place with input from 211 
many players within the Kingdom of Saudi Arabia [6].  Additionally, the occurrence of outbreak 212 
and emerging diseases is received from World Health Organization (WHO), European Centre for 213 
Disease Prevention and Control (ECDC), Public Health England (PHE) and United States 214 
Centers for Disease Prevention and Control (CDC) through the Public Health Directorate of the 215 
Ministry of Health.  These combined efforts are coordinated by 24 different committees [6].  The 216 
Saudi Ministry of Health then issues recommendations for the required vaccinations and other 217 
preventive measures.  The ministry also ensures compliance with these required vaccines. 218 
Multiple studies showed excellent compliance rates with the recommended vaccinations for the 219 
pilgrimage and was 97-100% in case of meningococcal vaccination among arriving international 220 
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pilgrims is 97-100% [9].  There is a concern that these verified numbers through vaccination 221 
cards might represent a false data.  In order to verify the reported compliance rates, a study of 222 
796 pilgrims showed that the majority of pilgrims were vaccinated and protected against 223 
meningococcal serogroups ACWY [76].  The 2017 Hajj season ended with no reported 224 
outbreaks.  The experience from each Hajj is growing each year and the planning for the 2018 225 
Hajj had already began.   The required vaccines will most likely remain the same with close 226 
monitoring for the development of any outbreaks internationally. 227 
228 
229 
230 
231 
232 
233 
234 
235 
236 
237 
238 
239 
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Table 1:  Health Requirements and Recommendations for Entry Visas for the Hajj and 470 
Umra seasons in 2017 471 
Countries or areas at risk Requirement 
Yellow fever Africa: 
Angola, Benin, Burkina Faso, 
Burundi, Cameroon, 
Central African Republic, Chad, 
Congo, Cote d’Ivoire, Democratic 
Republic of the Congo, Equatorial 
Guinea, Ethiopia, Gabon, Guinea, 
Guinea-Bissau, Gambia, Ghana, 
Kenya, Liberia, Mali, Mauritania, 
Niger, Nigeria, Rwanda, Senegal, 
Sierra Leone, Sudan, South Sudan, 
Togo and Uganda. 
South and Central America: 
Argentina, Venezuela, Brazil, 
Colombia, Ecuador, French Guiana, 
Guyana, Panama, Paraguay, Peru,  
Bolivia, Suriname, and Trinidad 
and Tobago. 
A valid yellow fever vaccination 
certificate (> 10 days after the date of 
vaccination).   If no proof of 
vaccination, persons will be placed 
under strict surveillance for 6 days 
from the last date of potential exposure 
to infection. 
Meningococcal 
meningitis 
a) Any visitor a) Certificate of vaccination with the
quadrivalent (ACYW135) vaccine was 
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(Either 
polysaccharide 
or conjugate 
vaccines) 
b) Visitors from African
meningitis belt: Benin, Burkina 
Faso, Cameroon, Chad, Central 
African Republic, Côte d’Ivoire, 
Eritrea, Ethiopia, Gambia, Guinea, 
Guinea-Bissau, Mali, Niger, 
Nigeria, Senegal and Sudan 
c) Interior pilgrims and the Hajj
workers: 
not given > 3 years (for polysaccharide 
vaccines) and not > 5 years (for 
conjugate vaccines) and not < 10 days 
before arrival in Saudi Arabia. 
b) ACYW135 vaccine (as above) AND
ciprofloxacin 500 mg (for individuals > 
12 years excluding pregnant women) as 
chemoprophylaxis to be given at the 
port of entry. 
c) Vaccination with quadrivalent
(ACYW135) vaccine is required if not 
vaccinated during the past 3 years with 
a polysaccharide vaccine or 5 years 
with a conjugate vaccine for: 
i) All citizens and residents of Medina
and Mecca. 
ii) All citizens and residents
undertaking the Hajj. 
iii) All Hajj workers.
-iv) Any individual working at entry 
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points or in direct contact with pilgrims 
in Saudi Arabia. 
Poliomyelitis a) Areas infected with Wild Polio
Virus 1 or circulating Vaccine 
Derived Polio Virus:  
Afghanistan, Nigeria and Pakistan. 
b) Areas vulnerable to re-
infection: Cameroon, Central 
African Republic, Chad, Guinea, 
Laos People’s Democratic 
Republic, Madagascar, Myanmar, 
Niger, and Ukraine. 
c) States which remain vulnerable
to Polio: Democratic Republic of 
the Congo, Equatorial Guinea, 
Ethiopia, Iraq, Kenya, Liberia, 
Sierra Leone, Somalia, South 
Sudan, Syrian Arab Republic and 
Yemen 
- proof of at least one dose of oral polio 
vaccine (OPV), or inactivated 
poliovirus vaccine (IPV), in the last 12 
months and > 4 weeks prior to 
departure, is required to apply for an 
entry visa to Kingdom of Saudi Arabia 
- All travelers will receive 1 dose of 
OPV on arrival to Saudi Arabia. 
Seasonal 
influenza 
All pilgrims (internal and 
international) and all health-care 
workers in the Hajj area 
It is recommends to have seasonal 
influenza vaccination 
Cholera No specific vaccine requirement 
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Figure 1: Annual Number of Pilgrims per year from 1996 to 2017 
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Figure 2: Prevalence of Influenza (%) as detected by PCR among Pilgrims in Various Studies 
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